Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Jiangxi Rimag Group Co., Ltd.
江西一脈陽光集團股份有限公司
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2522)

VOLUNTARY ANNOUNCEMENT
LAUNCH OF THE WORLD'S FIRST LARGE FOUNDATION MODEL-DRIVEN AI-ASSISTED DIAGNOSTIC PRODUCT BY MEDICAL IMAGE INSIGHTS

This announcement is made by the board (the "**Board**") of directors (the "**Directors**") of Jiangxi Rimag Group Co., Ltd. (the "**Company**", together with its subsidiaries collectively referred to as the "**Group**") on a voluntary basis.

The Board is pleased to announce that on October 16, 2025, Shanghai Medical Image Insights Intelligent Technology Co., Ltd. (上海影禾醫脈智能科技有限公司) ("**Medical Image Insights**"), an artificial intelligence company partially invested and incubated by the Group, officially launched the world's first AIR (AI-Assisted Diagnostic Product at the Path Level) product developed based on the medical imaging Large Foundation Model, "MIIA®" (影禾覓芽®) — the Non-contrast Chest CT Scan Assisted Diagnostic AIR ("**AIR Product**"). The AIR Product signifies the formal transition of medical imaging AI from the 1.0 era of "Single-Disease Small Model" to the 2.0 era of "Large Foundation Model-driven" technology. It features comprehensive diagnostic capabilities across all lesions, all diseases, and multi-organ collaborative diagnosis, marking a milestone breakthrough in the field of intelligent medical imaging diagnosis.

With the scanning area as the diagnostic unit, the first commercialised AIR Product focuses on non-contrast chest CT scans, enabling synchronous full-lesion detection and diagnosis of multiple organs such as the lungs, pleura, and mediastinum in a single scan, covering all common diseases in this area. Developed based on the world's first cross-modal and full-process medical imaging Large Foundation Model, "MIIA®" (影禾覓芽®), the AIR Product features multi-organ collaborative segmentation capabilities, fully demonstrating its technical advantages in efficient diagnosis, precise coverage, interactive collaboration, and seamless integration. This fundamentally reshapes the development and application logic of medical imaging AI.

The AIR Product is not only a diagnostic tool but also the first commercialised outcome of Medical Image Insights' Large Foundation Model ecosystem. By connecting top-tier hospitals with grassroots medical institutions through open interfaces, it forms a positive feedback loop of "data-driven model iteration and model-driven scenarios implementation (數據反哺模型迭代、模型推動場景落地)". This model will significantly shorten the AI product development cycle, reduce

development costs, and assist medical institutions in achieving standardised screening, intelligent diagnosis, and inclusive services. It will effectively promote industry chain collaboration and build a closed-loop ecosystem of "data – model – scenario".

The launch of the AIR Product marks the transition of medical imaging AI from "single-point breakthroughs" to "systematic empowerment", and from "tool assistance" to "diagnostic partnership". With its diagnostic logic centred around examination items, it aligns more closely with the film-reading workflows in clinical practice, driving the industry's transformation from "single-disease detection" to "multi-disease collaborative analysis", and providing a new paradigm for scenarios such as health screening, precision diagnosis, and telemedicine.

The technological innovation of the AIR Product, namely "achieving multi-disease synchronous diagnosis through a single scan", can significantly enhance the competitiveness and added value of the Group's imaging centre services. Leveraging its advantages in medical imaging data and scenarios, the Group will collaborate with Medical Image Insights to achieve synergistic empowerment, continuously optimise performance of its Large Foundation Model, and expand AI diagnostic products covering additional examination items. The Group will join hands with industry partners to jointly promote an "efficiency revolution" in medical imaging AI, making intelligent diagnosis more precise, faster, and more accessible.

About the Group and Medical Image Insights

The Group is a leading medical group specialised in medical imaging in China and the only operator and manager of a medical imaging platform that provides diversified imaging services and value to the entire medical imaging industry chain in China. The Group is principally engaged in the provision of imaging center services, imaging solution services and Rimag Cloud services. Medical Image Insights, an artificial intelligence company partially invested and incubated by the Group, is an emerging technology enterprise focused on the integration and development of medical imaging AI, and is dedicated to providing AI- and statistics-based medical imaging auxiliary tools, as well as self-developed medical imaging AI tools for radiologists.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Jiangxi Rimag Group Co., Ltd.
江西一脈陽光集團股份有限公司
Mr. CHEN Zhaoyang
Chairman of the Board, Executive Director and Chief Executive Officer

Hong Kong, October 16, 2025

As at the date of this announcement, the Board comprises Mr. CHEN Zhaoyang, Ms. HE Yingfei, Mr. FENG Xie and Mr. LI Feiyu as executive Directors, Mr. LIU Senlin and Mr. GUO Tao as non-executive Directors, and Mr. WU Xiaohui, Mr. LUO Yi and Ms. CHEN Yifei as independent non-executive Directors.